©2024 Stanford Medicine
Topical Insulin for Glaucoma
Recruiting
I'm InterestedTrial ID: NCT05206877
Purpose
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile
human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic
neuropathy, and optic disc drusen).
Official Title
Topical Insulin for Glaucoma and Optic Neuropathies
Stanford Investigator(s)
Jeffrey Goldberg, MD, PhD
Blumenkranz Smead Professor
Eligibility
Inclusion Criteria:
- Capable to provide informed consent
- Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.
- Only one eye per patient will be selected as the study eye - if both eyes meet the
inclusion criteria, the eye with the worse acuity and /or visual field will be
selected. The contralateral eye will be left untouched.
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Presence of any ocular pathologies other than glaucoma that contributes to the severe
vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)
- Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus
- Inability to perform reliable visual field
- Unable to provide informed consent
- Unable to complete the tests and follow-ups required by the study
Intervention(s):
drug: Insulin, 4 units
drug: Insulin, 20 units
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Esther Elenes